Cevimeline hydrochloride for Sjögren's syndrome
Examples
| cevimeline hydrochloride |
Evoxac |
Evoxac is given orally as a 30 mg capsule. Dosages vary
from 1 to 3 capsules a day.
How It Works
Cevimeline stimulates the
moisture-producing glands to increase saliva and tear production over a
sustained period of time.
Why It Is Used
Cevimeline is used to treat symptoms
of dry mouth and eyes caused by
Sjögren's syndrome.
You should
not take cevimeline if you have:
- Uncontrolled asthma.
- Narrow-angle
glaucoma or inflammation of the iris.
How Well It Works
Studies show that cevimeline improves
symptoms of dry mouth and eyes.1, 2
Side Effects
Side effects from cevimeline may
include:
- Excessive
sweating.
- Nausea.
- Runny
nose.
- Diarrhea.
- More frequent urination.
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
What To Think About
Talk to your doctor before taking cevimeline if you have:
- History of heart
disease.
- Asthma.
- Chronic
bronchitis.
- Chronic obstructive pulmonary disease
(COPD).
- Kidney problems.
If you are breast-feeding, pregnant, or trying to become
pregnant, talk to your doctor before taking cevimeline.
Before
taking cevimeline, review with your doctor all medicines that you take, both
prescription and nonprescription.
Complete the new medication information form (PDF)(What is a PDF document?)
to help you understand this medication.
References
Citations
-
Fife RS, et al. (2002). Cevimeline for the treatment
of xerostomia in patients with Sjögren's syndrome. Archives of Internal Medicine, 162: 1293–1300.
-
Petrone D, et al. (2002). A double-blind, randomized,
placebo-controlled study of cevimeline in Sjögren's syndrome patients with
xerostomia and keratoconjunctivitis sicca. Arthritis and Rheumatism, 46(3): 748–754.
Last Updated:
May 6, 2008
Fife RS, et al. (2002). Cevimeline for the treatment
of xerostomia in patients with Sjögren's syndrome. Archives of Internal Medicine, 162: 1293–1300.
Petrone D, et al. (2002). A double-blind, randomized,
placebo-controlled study of cevimeline in Sjögren's syndrome patients with
xerostomia and keratoconjunctivitis sicca. Arthritis and Rheumatism, 46(3): 748–754.